It is known that MASLD via mechanisms of increased oxidative stress, inflammation and lipotoxicity worsens insulin resistance (44), and cirrhosis, by decreasing hepatic insulin clearance, also contributes to insulin resistance (7). The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.